FDA warns Cosmobeauti Laboratories over manufacturing rule violations for OTC sunscreen drugs, including backdated batch records and missing microbial testing.
What happened
FDA inspected the drug manufacturing facility from March 6 to March 15, 2023. The agency found that the quality unit failed to oversee OTC SPF sunscreen drug production, and a consultant told investigators that review steps on batch production records were backdated. FDA also cited missing microbiological testing for each batch, insufficient shelf-life stability data, incomplete batch records, and inadequate water system and cleaning validation.
What FDA found
The quality unit failed to ensure that OTC sunscreen drug products were made in compliance with manufacturing rules and met specifications.
21 CFR 211.22Review steps on batch production records were backdated instead of recorded when performed.
21 CFR 211.22The firm did not perform microbiological testing on each finished drug batch.
21 CFR 211.165(b)The firm lacked sufficient stability data to support the assigned shelf-life of its OTC drug products.
21 CFR 211.166(b)Batch production records lacked major equipment, critical steps and parameters, and numerous steps were not recorded.
21 CFR 211.100(a) and 21 CFR 211.188The firm lacked adequate validation of the water system used to rinse non-dedicated equipment and lacked cleaning validation for that equipment.
21 CFR 211.100(a)
What FDA wants
FDA asks Cosmobeauti to correct the violations and respond in writing within 15 working days with corrective actions and evidence. FDA also recommends a qualified CGMP consultant to audit operations and evaluate corrective actions.
Who should pay attention
- brands that contract with Cosmobeauti to make OTC sunscreen drugs
- distributors and retailers selling its OTC sunscreen products
- contract manufacturers and quality teams handling similar documentation and cleaning validation
This is a summary. Read the original letter on fda.gov.